Jane Street’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Jane Street’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-180	Closed	-$13.6K	–	10398
2024 Q1	$13.6K	Buy	+180	New	+$23.7K	﹤0.01%	8942
2023 Q4	–	Sell	-11	Closed	-$8K	–	9961
2023 Q3	$8K	Buy	+11	New	+$47.2K	﹤0.01%	8406
2023 Q2	–	Sell	-5	Closed	-$12.6K	–	9775
2023 Q1	$12.6K	Buy	+5	New	+$14.6K	﹤0.01%	8715
2022 Q3	–	Sell	-6	Closed	-$17K	–	10675
2022 Q2	$17K	Hold	6	–	–	﹤0.01%	9206
2022 Q1	$18K	Sell	6 -8	-57%	-$34.4K	﹤0.01%	9969
2021 Q4	$85K	Buy	+14	New	+$107K	﹤0.01%	9321
2021 Q3	–	Sell	-23	Closed	-$198K	–	10924
2021 Q2	$234K	Sell	23 -106	-82%	-$1.74M	﹤0.01%	8582
2021 Q1	$2.47M	Buy	129 +125	+3,125%	+$1.46M	﹤0.01%	3635
2020 Q4	$23K	Buy	+4	New	+$15.7K	﹤0.01%	7365
2020 Q3	–	Sell	-3	Closed	-$12K	–	8099
2020 Q2	$12K	Buy	+3	New	+$9.96K	﹤0.01%	6987
2019 Q2	–	Sell	-13	Closed	-$168K	–	5893
2019 Q1	$168K	Buy	+13	New	+$210K	﹤0.01%	4695

Other funds holding SEEL

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

CHA

Carmichael Hill & Associates Gaithersburg, Maryland $282M AUM 32.52% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jane Street's SEEL Position: Q2 2024 in Review

Jane Street sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2024, closing a stake of 180 shares — an estimated $13.6K sold.

Jane Street first reported a position in SEEL in Q1 2019 and held it in 11 quarters. The position peaked at $2.47M in Q1 2021. 18 funds tracked by Wall St. Rank hold SEEL as of Q2 2024.

Jane Street reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Jane Street sold 180 Seelos Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $13.6K.
Jane Street first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2019 and held it in 11 quarters.
Jane Street's Seelos Therapeutics, Inc. Common Stock position peaked at $2.47M in Q1 2021.
18 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Jane Street's 13F filing for Q2 2024, filed 15 Aug 2024.